Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.64−0.02 (-3.31%)
Close on Nov 11, 2026Market cap $252.43MP/E 2.9Yield –
Standard BioTools statistics
87 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Q3 FY2026, expected soon
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- Nov 11, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 0.47
- 2.39
Enterprise valuationIndustry
- EV / Sales
- -2.65
- 2.65
Share statisticsIndustry
- Shares Change (YoY)
- 2.78%
- 10.9%
- Shares Change (QoQ)
- 0.51%
- 0.51%
- Float
- 117M
- 49M
- Shares Held by Insiders
- 70.2%
- 11.6%
- Shares Held by Institutions
- 75.4%
- 56.4%
Short sellingIndustry
- Short Interest
- 2M
- –
- Short Interest Change
- -11.3%
- -0.76%
- Short % of Float
- 1.86%
- 9.06%
- Short % of Shares Outstanding
- 0.55%
- 6.38%
- Days to Cover
- 3.07
- 5.16
Stock price statisticsIndustry
- 52-Week High
- $1.72
- –
- 52-Week Low
- $0.59
- –
- 20-Day Moving Average
- $0.63
- –
- 50-Day Moving Average
- $0.68
- –
- 200-Day Moving Average
- $0.88
- –
- Average True Range (14)
- $0.04
- –
- Price Change (1 Week)
- 4.38%
- -0.50%
- Price Change (1 Month)
- -2.41%
- -0.33%
- Price Change (3 Months)
- -14.2%
- -17.2%
- Price Change (6 Months)
- -36.3%
- -20.1%
- Price Change (YTD)
- -49.8%
- -20.1%
- Price Change (1 Year)
- -45.0%
- -19.3%
- Price Change (3 Years)
- -70.5%
- -23.4%
- Price Change (5 Years)
- -86.9%
- -76.4%
- Price Change (10 Years)
- -89.9%
- -62.4%
- Average Volume (10 Days)
- 894,817
- –
- Average Volume (20 Days)
- 796,724
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 0.29
- 0.73
- Relative Strength Index (14)
- 48.5
- 47.6
- Volatility (1 Year)
- 68.1%
- 80.2%
- Beta (5 Years)
- 1.53
- 1.07
MarginsIndustry
- Pretax Margin
- -107.5%
- -12.1%
- EBITDA Margin
- -106.4%
- -25.0%
- FCF Margin
- -97.6%
- -9.55%
Returns on capitalIndustry
- Return on Equity (ROE)
- 17.6%
- -51.3%
- Return on Assets (ROA)
- 14.3%
- -40.3%
- Return on Invested Capital (ROIC)
- -60.8%
- -34.0%
- Return on Capital Employed (ROCE)
- -16.7%
- -37.7%
Financial positionIndustry
- Current Ratio
- 9.10
- 3.30
- Quick Ratio
- 8.67
- 2.37
GrowthIndustry
- Revenue Growth (YoY)
- -4.78%
- 7.01%
- Revenue Growth (3Y CAGR)
- -4.49%
- 2.25%
- Revenue Growth (5Y CAGR)
- -9.19%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.14
- 0.40
- Inventory Turnover
- 2.03
- 2.68
- Revenue Per Employee
- $217.47K
- $426.63K
- Profits Per Employee
- $218.27K
- -$680.86K
- Employee Count
- 389
- 75
- WACC
- 12.5%
- 10.1%
Income statement (TTM)Industry
- Pretax Income
- -$90.98M
- -$13.50M
Balance sheetIndustry
- Net Cash (Debt)
- $476.72M
- $16.31M
- Net Cash Per Share
- $1.21
- $0.70
- Equity (Book Value)
- $539.97M
- $53.12M
- Book Value Per Share
- $1.38
- $1.49
- Tangible Book Value
- $539.97M
- $26.11M
- Working Capital
- $460.07M
- $77.59M
Cash flow (TTM)Industry
- Capital Expenditures
- -$2.28M
- -$939.00K
- FCF Per Share
- -$0.21
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- 33.6%
- -19.8%
- FCF Yield
- -32.7%
- -8.81%
Taxes and interestIndustry
- Income Tax
- -$37.05M
- $79.50K
Scores and fair valueIndustry
- Graham Number
- $2.61
- $19.42
- Graham Upside
- 305.8%
- -45.8%
- Altman Z-Score
- -0.34
- 0.28
- Piotroski F-Score
- 3
- 4
- Beneish M-Score
- -3.05
- -2.62
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LAB | S&P 500 | Difference | LAB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.7% | -2.4% | −4.3 pts | ||
| 3 months | -18.3% | -1.2% | −17.2 pts | ||
| Year to date | -49.8% | +12.3% | −62.1 pts | ||
| 1 year | -46.0% | +12.4% | −58.4 pts | ||
| 3 years | -70.5% | +78.8% | −149.3 pts | -33.4% | +21.4% |
| 5 years | -86.3% | +75.2% | −161.5 pts | -32.8% | +11.9% |
| 10 years | -89.9% | +311.1% | −401.0 pts | -20.5% | +15.2% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
2M LAB shares were sold short on Oct 30, 2026, down 11.3% from the previous report, or 1.86% of the shares available to trade. At recent volumes it would take 3.1 days to buy them back. Over the last 20 sessions, 34.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 2,169,887 | -11.3% | 706,767 | 3.1 |
| Oct 15, 2026 | 2,445,793 | -3.0% | 979,906 | 2.5 |
| Sep 30, 2026 | 2,520,686 | -2.8% | 925,491 | 2.7 |
| Sep 15, 2026 | 2,593,308 | -12.9% | 1,803,273 | 1.4 |
| Aug 31, 2026 | 2,979,028 | +23.9% | 1,702,005 | 1.8 |
| Aug 14, 2026 | 2,405,258 | -10.7% | 1,113,541 | 2.2 |
| Jul 31, 2026 | 2,694,489 | +21.7% | 2,015,651 | 1.3 |
| Jul 15, 2026 | 2,213,551 | -35.4% | 3,059,750 | 1.0 |
| Jun 30, 2026 | 3,425,003 | -65.9% | 6,850,088 | 1.0 |
| Jun 15, 2026 | 10,029,339 | -23.6% | 4,947,644 | 2.0 |
| May 29, 2026 | 13,127,631 | +1.6% | 2,222,425 | 5.9 |
| May 15, 2026 | 12,920,309 | +9.3% | 1,849,667 | 7.0 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?